NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Performance
NTLA vs. BMY - Performance Comparison
Loading graphics...
NTLA vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 47.61% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 270.82% | 7.47% | -28.98% | 46.61% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
NTLA:
$1.44B
BMY:
$125.99B
NTLA:
-$3.84
BMY:
$3.46
NTLA:
2.14
BMY:
2.26
NTLA:
$0.00
BMY:
$48.19B
NTLA:
-$34.30M
BMY:
$30.43B
NTLA:
-$322.22M
BMY:
$13.82B
Returns By Period
In the year-to-date period, NTLA achieves a 47.61% return, which is significantly higher than BMY's 15.79% return.
NTLA
- 1D
- 3.51%
- 1M
- -14.05%
- YTD
- 47.61%
- 6M
- -29.26%
- 1Y
- 99.40%
- 3Y*
- -29.12%
- 5Y*
- -30.19%
- 10Y*
- —
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NTLA vs. BMY — Risk / Return Rank
NTLA
BMY
NTLA vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NTLA | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 0.31 | +0.68 |
Sortino ratioReturn per unit of downside risk | 1.74 | 0.64 | +1.10 |
Omega ratioGain probability vs. loss probability | 1.25 | 1.08 | +0.17 |
Calmar ratioReturn relative to maximum drawdown | 1.22 | 0.25 | +0.97 |
Martin ratioReturn relative to average drawdown | 2.17 | 0.39 | +1.77 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NTLA | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 0.31 | +0.68 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.38 | 0.15 | -0.52 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.06 | 0.35 | -0.42 |
Correlation
The correlation between NTLA and BMY is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -96.45%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY.
Loading graphics...
Drawdown Indicators
| NTLA | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.45% | -72.03% | -24.42% |
Max Drawdown (1Y)Largest decline over 1 year | -71.27% | -25.79% | -45.48% |
Max Drawdown (5Y)Largest decline over 5 years | -96.45% | -47.67% | -48.78% |
Max Drawdown (10Y)Largest decline over 10 years | — | -47.67% | — |
Current DrawdownCurrent decline from peak | -92.49% | -12.07% | -80.42% |
Average DrawdownAverage peak-to-trough decline | -56.43% | -22.40% | -34.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.98% | 16.06% | +23.92% |
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 17.93% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NTLA | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.93% | 6.68% | +11.25% |
Volatility (6M)Calculated over the trailing 6-month period | 85.04% | 19.39% | +65.65% |
Volatility (1Y)Calculated over the trailing 1-year period | 101.32% | 28.61% | +72.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 80.73% | 23.68% | +57.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.27% | 25.08% | +53.19% |
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities